نتایج جستجو برای: lenalidomide
تعداد نتایج: 3060 فیلتر نتایج به سال:
The precise molecular mechanism of action and targets through which thalidomide and related immunomodulatory drugs (IMiDs) exert their antitumor effects remains unclear. We investigated the role of cereblon (CRBN), a primary teratogenic target of thalidomide, in the antimyeloma activity of IMiDs. CRBN depletion is initially cytotoxic to human myeloma cells, but surviving cells with stable CRBN ...
Cereblon (CRBN), the molecular target of lenalidomide and pomalidomide, is a substrate receptor of the cullin ring E3 ubiquitin ligase complex, CRL4(CRBN) . T cell co-stimulation by lenalidomide or pomalidomide is cereblon dependent: however, the CRL4(CRBN) substrates responsible for T cell co-stimulation have yet to be identified. Here we demonstrate that interaction of the transcription facto...
Bastuji-Garin, S., Fouchard, N., Bertocchi, M., Roujeau, J.C., Revuz, J. & Wolkenstein, P. (2000) SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. The Journal of Investigative Dermatology, 115, 149–153. Ca~ namares Orbis, I., Garc!ıa Mu~ noz, C., Cortijo Cascajares, S. & M!endez Esteban, M.E. (2012) Desensitization to lenalidomide. Farmacia Hospitalaria, 36, 542–543. Spanish...
Lenalidomide has been developed as the derivative of thalidomide that has fewer side effects. We herein report a rare case of castration-resistant prostate cancer successfully maintained using lenalidomide for multiple myeloma.
lenalidomide. The results of this trial indicate that CLL patients who have initially received lenalidomide can have enhanced clinical responses with the addition of rituximab (Chanan-Khan, verbal communication, July 2008). Until there is a clear dissection of the exact mechanisms of rituximab-mediated clearances of CLL B cells, it would seem premature to alter current strategies. However, this...
Optimal salvage treatment for multiple myeloma relapsing after allogeneic stem cell transplantation remains to be determined. Usually, such patients have been heavily pre-treated and present at relapse with a relatively refractory disease. Immunomodulatory properties of lenalidomide may be beneficial by facilitating a graft-versus-myeloma effect after allogeneic stem cell transplantation. Howev...
Clinical studies involving patients with myelodysplastic syndromes or multiple myeloma have shown the efficacy of lenalidomide by reducing and often eliminating malignant cells while restoring the bone marrow function. To better understand these clinical observations, we investigated and compared the effects of lenalidomide and a structurally related analogue, CC-4047, on the proliferation of t...
The few studies that have examined rates of acute myeloid leukemia (AML) transformation in lenalidomide-treated myelodysplastic syndrome (MDS) patients have been limited to deletion 5q MDS. The association between lenalidomide and subsequent primary malignancies (SPMs) in MDS patients has not been evaluated previously. We conducted a retrospective cohort study to evaluate the risk of both SPM a...
Lenalidomide is an immunomodulatory drug administered orally in the treatment of multiple myeloma. Some elderly patients require a reduced lenalidomide dose because of comorbidities and/or adverse events. This study investigated the actual dose of lenalidomide in elderly patients, finding that most received reduced (5-10 mg) doses. The most common reasons for dose reduction were renal dysfuncti...
A 50-year-old woman received low dose lenalidomide for palliative treatment of advanced IgG myeloma. Despite a long and convoluted treatment history including second courses of autologous peripheral blood stem cell transplantation, bortezomib and thalidomide, the patient responded well to 2 courses of lenalidomide therapy, but developed severe thrombocytopenia. Therefore, lenalidomide treatment...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید